Delisting of Wilson Therapeutics

Jun 01, 2018

Nasdaq Stockholm has decided that Wilson Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the shares will be 15 June 2018.

About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. On April 11 2018, Alexion announced a public offer to the shareholders in Wilson Therapeutics. This offer was declared unconditional on May 25, 2018 and the company will be delisted from Nasdaq Stockholm on June 15, 2018.

Visit www.wilsontherapeutics.com for more information.

For further information please contact:

Jonas Hansson, CEO, Wilson Therapeutics AB

Phone: +46 8 796 00 00
E-mail: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
Kungsgatan 3
SE-111 43 Stockholm